<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935194</url>
  </required_header>
  <id_info>
    <org_study_id>Z09000700090903</org_study_id>
    <nct_id>NCT00935194</nct_id>
  </id_info>
  <brief_title>Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study</brief_title>
  <official_title>Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Infection: Multi-centre, Prospective, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Chinese medicinal herbs are effective and
      safe for treating novel influenza A (H1N1) infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The antiviral agent, oseltamivir, is recommended by the World Health Organization (WHO) to
      treat recent outbreak novel influenza A (H1N1) virus infection around world. But limited
      stock and resistant strain emergence raised increasing concerns. Chinese medicinal herbs, are
      derived from plants and usually incorporate one or more herbs as the basic drug(s) to treat
      the disease. The investigators performed RCT to indicate that Chinese medicinal herbs was
      effective and safe for treating novel influenza A (H1N1) infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to resolution of fever (the period from start of study-drug to relief of fever)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to resolution of respiratory symptoms(defined as the period from start of study-drug to relief of symptoms)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virus shedding time</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>blank</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>do not take antiviral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antiviral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chinese medicinary herbs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antiviral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oseltalmivir and chinese medicinal herbs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination antiviral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oseltamivir</intervention_name>
    <description>75mg,bid,for 5 days</description>
    <arm_group_label>Oseltamivir</arm_group_label>
    <other_name>TamifluTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blank</intervention_name>
    <description>no antiviral therapy</description>
    <arm_group_label>blank</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chinese medicinal herbs</intervention_name>
    <description>200ml,p.o,qid,for 5 days</description>
    <arm_group_label>chinese medicinary herbs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oseltamivir and chinese medicinal herbs</intervention_name>
    <description>oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days</description>
    <arm_group_label>oseltalmivir and chinese medicinal herbs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed novel influenza A(H1N1) case with laboratory evidence

          -  70 years ≥ age ≥ 14years

          -  Within 72hr after the onset of symptoms(body temperature≥37.5℃ with at least one
             respiratory symptom (cough, sore throat, or nasal symptom)

        Exclusion Criteria:

          -  Age &lt; 14 years or &gt; 70 years

          -  Bronchitis, pneumonia, pleural fluid and interstitial infiltration showed by Chest
             radiology(x-ray or CT)

          -  Severe chronic underlying diseases: severe COPD(FEV1/EVC &lt;70% and FEV1 &lt;30% predicted
             or respiratory failure or congestive heart failure), severe hepatic disfunction（ALT or
             AST ≥3 times normal elevation), renal disfunction（Cr&gt;2mg/dL), chronic heart
             failure(NYHA Ⅲ-Ⅳ grade）

          -  Immunocompromised patients(cancer, organ transplant, AIDS and a history of treatment
             with immunosuppressive drug and glucocorticoids in the past 3 months)

          -  Taken Chinese medicinal herbs, antiviral or antibiotic drug in the past 2 weeks

          -  Inoculation influenza vaccination

          -  One of the following items appeared at the enrollment

               -  respiratory failure：PaO2&lt;60mmHg and/or PCO2&gt;50mmHg or PaO2/FiO2≤300

               -  circulation failure: despite adequate fluid resuscitation and cardiac output,
                  systolic &lt;90mmHg or requirement inotropic support

               -  renal function failure: despite adequate fluid resuscitation and cardiac output,
                  urine ≤ 0.5ml/kg.h, Cr or BUN≥1 time normal elevation

               -  hepatic function failure: total bilirubin&gt;34μmol/L or ALT/AST ≥3 times normal -
                  Other unappropriated enrollment situations considered by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Wang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qingquan Liu, Docter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chinese Traditional Medicine University affiliated Dongzhimen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Mao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Ditan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>November 30, 2009</last_update_submitted>
  <last_update_submitted_qc>November 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wang Chen</name_title>
    <organization>Capital Medical University Affiliated Beijing Chaoyang Hospital</organization>
  </responsible_party>
  <keyword>Novel Influenza A(H1N1)</keyword>
  <keyword>Oseltamivir</keyword>
  <keyword>Chinese Medicinal Herbs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

